Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-24

Clostridial-directed enzyme prodrug therapy (cdept): a novel approach to cancer treatment.

Objetivo

Current systems for delivering therapeutic genes to tumours suffer from a number of serious deficiencies, most notably a lack of specificity for cancer cells. Here we propose an innovative solution to the problem based on the use of the spores of a harmless, non-pathogenic Clostridium species, Clostridium acetobutylicum. Intravenously injected clostridia spores localise to, and exclusively germinate in, the hypoxic regions of solid tumours. The spores are incapable of germinating in healthy tissue. We will engineer this harmless organism such that it produces a variety of prod rug-converting enzymes and assess their anti-tumour effects in a rat tumour model. New, more efficient enzymes and prod rugs will be developed. To increase safety, the clostridia host will be derivative such that it cannot speculate outside of the confines of the laboratory "flask".

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

UNIVERSITY OF NOTTINGHAM
Aportación de la UE
Sin datos
Dirección
Queen's Medical Centre - University Hospital
NG7 2UH NOTTINGHAM
Reino Unido

Ver en el mapa

Coste total
Sin datos

Participantes (4)